Ascentage Pharma Group International (AAPG) FinancialsAAPGFinancialAscentage Pharma Group International

Evaluating the bottom line, Ascentage Pharma Group International maintains a gross margin of 96.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -260.99%, while the net margin is -270.34%. These profitability ratios, combined with a Return on Equity (ROE) of -240.30%, provide a clear picture of how effectively AAPG converts its operational activities into shareholder value.

In the context of the broader market, AAPG competes directly with industry leaders such as EXEL and MDGL. With a market capitalization of $1.75B, it holds a significant position in the sector. When comparing efficiency, AAPG's gross margin of 96.12% stands against EXEL's 96.71% and MDGL's 89.02%. Such benchmarking helps identify whether Ascentage Pharma Group International is trading at a premium or discount relative to its financial performance.

Ascentage Pharma reported FY 2025 earnings that beat expectations, with a GAAP EPS of $0.50, despite a revenue decline of 38.9% year-over-year to $82.1 million, indicating resilience in profitability management.